Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 122

Results For "ED"

8108 News Found

Dabur India consolidated Q3FY23 PAT lower at Rs. 475.94 Cr
News | February 03, 2023

Dabur India consolidated Q3FY23 PAT lower at Rs. 475.94 Cr

The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022


Apollo Hospitals partners with MediSage
News | February 03, 2023

Apollo Hospitals partners with MediSage

Experts’ conclave to pave holistic approach to cancer management


Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr
News | February 02, 2023

Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr

The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022


Hester Biosciences Q3 FY23 consolidated net profit up at Rs. 11.18 Cr
News | February 02, 2023

Hester Biosciences Q3 FY23 consolidated net profit up at Rs. 11.18 Cr

The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022


Budget 2023-24: Industry welcomes focus on medical research and pharma innovation
Policy | February 02, 2023

Budget 2023-24: Industry welcomes focus on medical research and pharma innovation

It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047


Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr
News | January 29, 2023

Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr

The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022


Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr
News | January 28, 2023

Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr

The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022


Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in US
News | January 28, 2023

Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in US

The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA


Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr
News | January 27, 2023

Dr. Reddys Laboratories Q3 FY2023 consolidated PAT up to Rs. 1243.9 Cr

The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022


Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr
News | January 27, 2023

Torrent Pharmaceuticals posts Q3FY23 consolidated PAT at Rs. 283 Cr

The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022